Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus.
Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus.
复制标题
杂交瘤类型特异性抗体对 B 族链球菌实验性感染的保护作用。
DOI：
10.1093/infdis/149.3.363
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
Hill,HR
中科院分区：
文献类型：
--
作者：
Shigeoka,AO;Pincus,SH;Rote,NS;Hill,HR
用免疫BALB/c小鼠的脾淋巴细胞与小鼠骨髓瘤细胞系SP 2/0融合，制备了抗B群链球菌III型的单克隆抗体。四个III型特异性抗体，这是IgM类，保护新生大鼠腹腔内感染同源型B组链球菌;存活率为95%-100%的保护大鼠，但只有17%的未保护大鼠。一种抗体制剂对所用的五种III型菌株中的任何一种都提供了极好的保护。单克隆抗体在感染后4、8或12小时给药时提供保护，尽管延迟给药对毒性更强的菌株效果较差。单克隆IgM也可防止鼻内接种细菌。这些结果表明单克隆抗体在新生儿B组链球菌病中的潜在治疗效果，但在人类单克隆或多克隆抗体治疗的临床研究之前必须进行进一步的实验室研究。
Murine monoclonal antibodies to group-BStreptococcustype III were developed by fusion of splenic lymphocytes from immunized BALB/c mice with the mouse-myeloma cell line SP 2/0. The four type III-specific antibodies, which were of the IgM class, protected neonatal rats against intraperitoneal infection with homologous-type group-B streptococci; survival rates were 95%–100% for protected rats but only 17% for unprotected rats. One antibody preparation offered excellent protection against any of five type-III strains employed. Monoclonal antibody provided protection when administered 4, 8, or 12 hr after infection, although delayed administration was less efficacious against more virulent strains. Monoclonal IgM also protected against intranasal inoculation of bacteria. These results indicate the potential therapeutic efficacy of monoclonal antibody in neonatal group-B streptococcal disease, but further laboratory investigations must precede clinical investigation of monoclonal or polyclonal antibody therapy in humans.